Sanofi Bets Big on Alzheimer's Disease with $1.04B Deal for ADEL-Y01 and TREM2 Agonist VG-3927

Major pharmaceutical companies are continuously increasing their investment in Alzheimer's disease (AD) Drug Development.

December 15,Korean Biotechnology CompanyADEL Announces Global Exclusive License Agreement with Sanofi to Co-develop a Product inClinicalResearchEarly StageStageAD First-line Antibody Therapy ADEL-Y01. The total potential value of this agreement is up to 1.04 billion US dollars, marking Sanofi's second key layout in the AD field this year.

This YearIn May, Sanofi acquired Vigil Neuroscience for $470 million.Company,Core assets are targetedVG-3927, an oral small molecule agonist of TREM2, is intended for the treatment of neurodegenerative diseases such as AD.

Sanofi is not alone. Facing huge unmet clinical needs and market potential, global pharmaceutical giants are allActive Layout in the AD Field. AbbVie Acquires Aliada Therapeutics for $1.4 Billion in December 2024Company, and obtain its status inPhase I Clinical Anti-Pyroglutamate Amyloid-beta Therapy; Johnson & Johnson Acquires for $14.6 Billion in May 2025Focus on the development of the central nervous system (CNS) Disease Treatment DrugsIntra-Cellular TherapiesCompany。

DespiteThe AD field, once dubbed the "R&D black hole" due to its extremely high failure rate, has seen Eisai/Biogen and Eli Lilly take the lead. With their marketed drugs, they have preliminarily demonstrated the feasibility of disease-modifying therapies, opening a new door of hope for the industry. As heavy investments pour in from companies like Sanofi, AbbVie, and Johnson & Johnson, the competition in the AD space is shifting from a "two-power rivalry" to a "multi-power race," and the future R&D and market landscape will continue to evolve.

AD is a common degenerative neurological disease, with its incidence significantly increasing with age. According to estimates by the World Health Organization (WHO), there were 55 million cases worldwide in 2023.NameAD patients; and with the continuous intensification of global population aging, this number may increase to 130 million by 2050., presenting everyA 20-year doubling growth trend,Will bring a heavier burden to patients, families, and society.

In response to this huge and unmet clinical demand, pharmaceutical companies around the world are stepping up their efforts. Sanofi's acquisition this timeADEL-Y01 is a promising AD antibody therapy with the potential to become a "first-in-class" treatment.

ADEL-Y01 is a humanized monoclonal antibody and does not broadly target alltau protein, but selectively targets acetylationtau protein at lysine-280 (acK280) site.Targeting alltUnlike the therapy of au protein, ADEL-Y01 specifically inhibits toxictAggregation and Spread of au Species,While avoiding interference with normaltAU protein maintains the physiological function of microtubule stability.Targeting PathologicaltAU is one of the important strategies in the current AD drug development.。

In fact, this is already Sanofi's second move within a year. Previously, onIn May 2025, Sanofi acquired Vigil Neuroscience at a premium of up to 246%, with a total amount of approximately $470 million.Company, willVG-3927 secured.

It is worth mentioning that, in the past, forADThe drug research and development is mostly concentrated inTargets such as Aβ (Amyloid-beta), tau protein, etc.。AndVG-3927: The world's first orally administered small-molecule agonist targeting TREM2 (Triggering Receptor Expressed on Myeloid Cells 2).

InOn the emerging track of TREM2, the competition is not smooth. Previously, Takeda/DenaliCompanyTheNL919 Monoclonal Antibody, AbbVie/AlectorCompanyTheThe fact that projects like AL002 monoclonal antibody have not met expectations makes the positive clinical progress achieved by VG-3927 particularly crucial. If oral TREM2 drugs like VG-3927 are successfully developed, they will provide patients with a new treatment option and even have the potential to disrupt existing treatment models, thanks to the convenience of oral administration and their unique mechanism of action.

ADCalled"One of the most challenging medical problems in the 21st century," Sanofi's consecutive moves this time are both a testament to trust in scientific innovation and a response to unmet clinical needs. DespiteADEL-Y01 andVG-3927 still needs to pass the test of clinical trials, but the cutting-edge bets on these new targets bring potential novel treatment options for the future, which are worth looking forward to.

According to the Business Research Insights report,In 2025, Global ADDrug SalesFor$8.67 billion, expected to reach $14.06 billion by 2034, with a compound annual growth rate of 6.23% during the forecast period.

ADGlobalDrug Sales（2025-2034E) Data Source:Business Research Insights

In the face of this promising billion-dollar market,Lilly and Eisai/Biogen has leveraged its first-mover advantage to establish an unshakable "duopoly" position in the current AD treatment landscape.

July 2023,Eisai/BiogenTheLecanemab has been approved for marketing, becomingThe First New AD Therapy to Receive Full FDA Approval in 20 Years. In January 2024, Lecanemab was approved for marketing in China. With this, China has become the third country to approve the drug after the United States and Japan.

Data from MiNe Network shows,Global Sales of Lecanemab in 2023 Reach 4.3 Billion Yen（Approximately294Ten ThousandDollar），Increased to 44.3 billion yen in 2024 (Approximately$300 million), with a growth rate as high as 930%. In China's three major terminals and six major markets, the sales of Lecanemab exceeded 50 million yuan in the first three quarters of 2024, and achieved a result of 53 million yuan in the first quarter of 2025.

Closely following EisaiFollowing Biogen, Eli Lilly submitted its marketing application for the Aβ monoclonal antibody donanemab to the FDA in July 2023. On December 17, 2024, the drug was approved by the NMPA as a Class 1 new drug and breakthrough therapy for mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease (AD) in adults. In March this year, Eli Lilly China announced that its innovative drug donanemab injection, used in the early stages of AD, targeting the pathological mechanisms of the disease, and capable of significantly slowing disease progression, has officially launched in China.

Notably, China's first edition of the commercial insurance innovative drug directory has simultaneously included lecanemab and donanemab, indicating that the two drugs...AD DrugIt is expected to further expand the payment space with the help of commercial insurance, paving the way for the next round of explosive growth in the billion-dollar market."Fast Lane."

“Duopoly”ThePattern，Not givenThe End of the AD Battlefield, but instead has given rise to a more diverse and fragmented new ecosystem.

Besides Sanofi inExpansion in the AD Oral Medication Field: Johnson & Johnson Collaborates with AC Immune for Developmenttau protein vaccine JNJ-2056, has enteredⅡPhase B clinical active immunotherapy aims to delay or prevent cognitive decline in asymptomatic patients, with its strategic intent shifting from "treatment" to the more forward-thinking "prevention." Hengrui Medicine, a leading innovator in China's pharmaceutical industry, is also making continuous efforts in this field. Its self-developed Aβ monoclonal antibody SHR-1707 has currently advanced toⅡPhase clinical. Self-developed by Akeso Biopharma.AK152 Approved for Clinical Trials,Becoming the first in China to enter the clinical stageAD bispecific antibody drugs; companies like Xiantong Pharmaceuticals and Atommab BioPharma are also on the way to developing solutions for the early diagnosis of AD.

Editor: Zhang Jieying

Layout Editor: Yu Yuanze

Reviewed by: Ma Fei, Zhang Song

Ten Departments Issue Document to Improve Online Sales Quality! Crack Down on False Advertising and False Promotion of "Two Products and One Device"

Has the Strategic Shift of Pharmaceutical Companies Towards Specialized Division Begun? Hisun's "Alliance" with Jiuzhou Tong, and Fosun Kite's Renewed Partnership with Sinopharm

An Infographic to Understand the "Double Directories" Initial Lineup: What Are the Thresholds for Choosing Between Medical Insurance and Commercial Insurance?

www.yyjjb.com.cn

Insight into Industry Trends

Press and hold to followPharmaceutical Economy Report

China Prescription Drug

Academic Official Account

Focus on Pharmaceutical Academics and Evidence-Based Research

Press and hold to followChina Prescription Drug

"Pharmaceutical Economy Herald"

Terminal Official Account

Record Major Events in the Pharmaceutical Industry

Press and hold to follow21st Century Pharmacy